Amgen Inc. (AMGN) Operating Margin
- Operating margin · 12 months: Value 29.99%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 29.99% | Operating income / revenue. Period ending 2026-06-30. $11.43B ÷ $38.09B × 100 ≈ 29.99% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 11.43B USD | Operating Income (Loss) |
| Revenue | 38.09B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 11.61B USD | Cost of Goods and Services Sold |
| Research and development | (m) | |
| Selling, general and administration | 7.02B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $11.43B | $38.09B | $11.61B | (m) | $7.02B | 29.99% |
| 2026-03-31 | $10.57B | $37.22B | $11.81B | (m) | $6.96B | 28.39% |
| 2025-12-31 | $9.08B | $36.75B | $12.04B | (m) | $7.05B | 24.71% |
| 2025-09-30 | $8.67B | $35.97B | $12.17B | (m) | $6.98B | 24.11% |
| 2025-06-30 | $8.19B | $34.92B | $12.40B | (m) | $6.88B | 23.46% |
| 2025-03-31 | $7.45B | $34.13B | $12.63B | (m) | $6.97B | 21.82% |
| 2024-12-31 | $7.26B | $33.42B | $12.86B | (m) | $7.10B | 21.71% |
| 2024-09-30 | $6.22B | $32.53B | $12.86B | (m) | $7.49B | 19.11% |
| 2024-06-30 | $6.19B | $30.93B | $11.35B | (m) | $7.22B | 20.02% |
| 2024-03-31 | $6.97B | $29.53B | $9.93B | (m) | $6.73B | 23.59% |
| 2023-12-31 | $7.90B | $28.19B | $8.45B | (m) | $6.18B | 28.01% |
| 2023-09-30 | $8.86B | $26.83B | $7.09B | (m) | $5.48B | 33.00% |
| 2023-06-30 | $9.49B | $26.58B | $6.87B | (m) | $5.41B | 35.72% |
| 2023-03-31 | $8.99B | $26.19B | $6.57B | (m) | $5.44B | 34.31% |
| 2022-12-31 | $9.57B | $26.32B | $6.41B | (m) | $5.41B | 36.34% |
| 2022-09-30 | $9.64B | $26.33B | $6.38B | (m) | $5.27B | 36.61% |
| 2022-06-30 | $9.36B | $26.38B | $6.40B | (m) | $5.29B | 35.47% |
| 2022-03-31 | $8.01B | $26.32B | $6.53B | (m) | $5.34B | 30.44% |
| 2021-12-31 | $7.64B | $25.98B | $6.45B | (m) | $5.37B | 29.40% |
| 2021-09-30 | $7.34B | $25.77B | $6.33B | (m) | $5.72B | 28.50% |
| 2021-06-30 | $7.42B | $25.48B | $6.29B | (m) | $5.76B | 29.11% |
| 2021-03-31 | $8.91B | $25.16B | $6.14B | (m) | $5.67B | 35.42% |
| 2020-12-31 | $9.14B | $25.42B | $6.16B | (m) | $5.73B | 35.95% |
| 2020-09-30 | $9.18B | $24.99B | $5.82B | (m) | $5.47B | 36.74% |
| 2020-06-30 | $9.20B | $24.30B | $5.29B | (m) | $5.35B | 37.87% |
| 2020-03-31 | $9.56B | $23.97B | $4.81B | (m) | $5.31B | 39.88% |
| 2019-12-31 | $9.67B | $23.36B | $4.36B | (m) | $5.15B | 41.41% |
| 2019-09-30 | $10.01B | $23.39B | $4.20B | (m) | $5.20B | 42.78% |
| 2019-06-30 | $9.86B | $23.56B | $4.20B | (m) | $5.27B | 41.83% |
| 2019-03-31 | $10.01B | $23.75B | $4.21B | (m) | $5.36B | 42.14% |
| 2018-12-31 | $10.26B | $23.75B | $4.10B | (m) | $5.33B | 43.22% |
| 2018-09-30 | $10.13B | $23.32B | (m) | (m) | $5.20B | 43.42% |
| 2018-06-30 | $10.24B | $23.19B | (m) | (m) | $5.08B | 44.17% |
| 2018-03-31 | $10.11B | $22.94B | (m) | (m) | $4.93B | 44.06% |
| 2017-12-31 | $9.97B | $22.85B | (m) | (m) | $4.87B | 43.65% |
| 2017-09-30 | $10.21B | $23.01B | (m) | (m) | $4.77B | 44.38% |
| 2017-06-30 | $10.30B | $23.05B | (m) | (m) | $4.84B | 44.69% |
| 2017-03-31 | $9.98B | $22.93B | (m) | (m) | $4.92B | 43.54% |
| 2016-12-31 | $9.79B | $22.99B | (m) | (m) | $5.06B | 42.60% |
| 2016-09-30 | $9.34B | $22.56B | (m) | (m) | $5.16B | 41.41% |
| 2016-06-30 | $9.15B | $22.47B | (m) | (m) | $5.16B | 40.73% |
| 2016-03-31 | $8.85B | $22.16B | (m) | (m) | $5.02B | 39.94% |
| 2015-12-31 | $8.47B | $21.66B | (m) | (m) | $4.85B | 39.10% |
| 2015-09-30 | $7.90B | $21.46B | (m) | (m) | $4.76B | 36.80% |
| 2015-06-30 | $7.02B | $20.77B | (m) | (m) | $4.73B | 33.82% |
| 2015-03-31 | $6.85B | $20.57B | (m) | (m) | $4.70B | 33.29% |
| 2014-12-31 | $6.19B | $20.06B | (m) | (m) | $4.70B | 30.86% |
| 2014-09-30 | $5.92B | $19.74B | (m) | (m) | $4.89B | 29.98% |
| 2014-06-30 | $6.14B | $19.46B | (m) | (m) | $4.93B | 31.56% |
| 2014-03-31 | $5.79B | $18.96B | (m) | (m) | $5.05B | 30.53% |
| 2013-12-31 | $5.87B | $18.68B | (m) | (m) | $5.18B | 31.41% |
| 2013-09-30 | $5.77B | $18.09B | (m) | (m) | $5.02B | 31.89% |
| 2013-06-30 | $5.50B | $17.66B | (m) | (m) | $4.91B | 31.17% |
| 2013-03-31 | $5.54B | $17.45B | (m) | (m) | $4.88B | 31.75% |
| 2012-12-31 | $5.58B | $17.27B | (m) | (m) | $4.80B | 32.30% |
| 2012-09-30 | $5.65B | $16.82B | (m) | (m) | $4.64B | 33.60% |
| 2012-06-30 | $4.75B | $16.44B | (m) | (m) | $4.64B | 28.91% |
| 2012-03-31 | $4.50B | $15.92B | (m) | (m) | $4.54B | 28.23% |
| 2011-12-31 | $4.31B | $15.58B | (m) | (m) | $4.49B | 27.67% |
| 2011-09-30 | $4.22B | $15.45B | (m) | (m) | $4.43B | 27.30% |
| 2011-06-30 | $5.17B | $15.32B | (m) | (m) | $4.27B | 33.76% |
| 2011-03-31 | $5.36B | $15.17B | (m) | (m) | $4.12B | 35.32% |
| 2010-12-31 | $5.54B | $15.05B | (m) | (m) | $3.98B | 36.84% |
| 2010-09-30 | $5.60B | $15.02B | (m) | (m) | $4.01B | 37.28% |
| 2010-06-30 | $5.73B | $15.02B | (m) | (m) | $3.98B | 38.13% |
| 2010-03-31 | $5.67B | $14.93B | (m) | (m) | $3.91B | 37.96% |
| 2009-12-31 | $5.51B | $14.64B | (m) | (m) | $3.82B | 37.60% |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $5.21B | $15.00B | (m) | (m) | $3.79B | 34.75% |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | $3.98B | $14.77B | (m) | (m) | $3.36B | 26.94% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |